Lyme disease (LD) is a tick-borne illness caused by the bacterium Borrelia burgdorferi, which can cause severe symptoms if untreated. We present a novel diagnostic platform utilizing synthetic peptides and a deep-learning-based analytical algorithm to detect LD-specific antibodies in patient serum samples. Blinded samples acquired from the Centers for Disease Control and Prevention (CDC) were tested using our platform, achieving a sensitivity of 95% among disseminated disease and a specificity of 100% across all healthy endemic controls and cross-infected samples. Our peptide-based assay offers high sensitivity, specificity, ease-of-use, and cost-effectiveness, making it an attractive platform for point-of-care LD diagnosis.
|